To determine whether TP53 mutation has predictive value in HER2+ breast cancer patients, we first analyzed ctDNA sequencing results and the efficacy of pyrotinib in phase Ib, phase Ic, and phase II clinical trials led by our center. The gene discussed is TP53; the disease is breast carcinoma.